Exploring the use of Ingenol Mebutate to prevent non-melanoma skin cancer: A review

Abstract

Globally, the incidence of non-melanoma skin cancer is increasing rapidly. Actinic keratosis (AK) is a type of sun damaged skin disease with a greater probability of turning into squamous cell cancer. However it is difficult to determine which AK will progress to SCC, although the presence of AK is an indication of SCC risk. Moreover, surgical excision is the major therapy, the innovative therapeutic agents has been prompted by the increase in patient desire for efficient, tissue preserving methods with superior therapeutic results. In this context, Ingenol mebutate is an innovative skin treatment with immunostimulatory and chemoablative properties. It is derived from the plastic sap of the plant Euphorbia peplus, which is known for its ability to kill cancer cells. Clinical trials have shown Ingenol mebutate is safe and effective, prompting the FDA to approve this chemotherapeutic specialist for AK treatment in 2012. Recent effective experts for AK field therapy should be used for a long period, whereas ingenol should be used for three days. Ingenol is another useful option that is favorable, safe, feasible, sufficient, and long-lasting. The present review provides a comprehensive overview about the current use and future prospects of Ingenol mebutate as a potential treatment option to treat non-melanoma skin cancer, specifically AK. The current review covers the mechanism of action and preclinical studies of Ingenol mebutate with a particular focus on the clinical studies that warrant the safety and efficacy of Ingenol mebutate for the treatment of AK.